Longboard Pharmaceuticals, Inc. Research & Development Expenses (R&D)
| Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|
| Research & Development Expenses (R&D) | $4,633.0K | $19.8M | $34.6M | $43.8M |
Longboard Pharmaceuticals, Inc. (LBPH) Research & Development Expenses (R&D) comparison analysis
General
LTM Research & Development Expenses (R&D)
Growth
Company name
YoY growth
3Y CAGR
5Y CAGR
LBPH key stats
| Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|
% growth | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% |
| Cost of Goods Sold (COGS) | 0.0 | 0.0 | 0.0 | 0.0 |
% margin | 0.0 0.0% | (0.0) 0.0% | (0.0) 0.0% | (0.0) 0.0% |
| Operating Expenses | 14.4 | 27.8 | 44.8 | 56.8 |
| Research & Development Expenses (R&D) | 4.6 | 19.8 | 34.6 | 43.8 |
| Selling, General & Administrative Expenses (SG&A) | 9.8 | 8.1 | 10.2 | 13.0 |
% margin | (14.4) 0.0% | (27.8) 0.0% | (44.8) 0.0% | (56.8) 0.0% |
| Interest Income | 0.0 | 0.1 | 0.8 | 2.4 |
| Interest Expense | 0.0 | 0.0 | 0.8 | 0.0 |
| Pre-tax Income | (14.4) | (27.8) | (43.9) | (54.4) |
% effective tax rate | (0.0) 0.1% | (0.1) 0.2% | (0.9) 1.9% | 0.0 0.0% |
% margin | (14.4) 0.0% | (27.7) 0.0% | (43.1) 0.0% | (54.4) 0.0% |
| EPS | (0.82) | (1.62) | (2.51) | (2.39) |
| Diluted EPS | (0.82) | (1.62) | (2.51) | (2.39) |
% margin | (14.4) 0.0% | (27.8) 0.0% | (44.8) 0.0% | (56.8) 0.0% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
FAQ
1) What is Longboard Pharmaceuticals, Inc.'s Research & Development Expenses (R&D)?
As of today, Longboard Pharmaceuticals, Inc.'s last 12-month Research & Development Expenses (R&D) is $67.3M, based on the financial report for Sep 30, 2024 (Q3’2024).
2) What is Longboard Pharmaceuticals, Inc.'s Research & Development Expenses (R&D) growth rate?
Over the last year, Longboard Pharmaceuticals, Inc.'s Research & Development Expenses (R&D) growth was 65.1%. The average annual Research & Development Expenses (R&D) growth rates for Longboard Pharmaceuticals, Inc. have been 95.7% over the past three years, 308.7% over the past five years.
3) Is Longboard Pharmaceuticals, Inc.'s Research & Development Expenses (R&D) growth rate Good?
Over the last year, Longboard Pharmaceuticals, Inc.'s Research & Development Expenses (R&D) growth was 65.1%, which is higher than industry growth of (0.1%). It indicates that Longboard Pharmaceuticals, Inc.'s Research & Development Expenses (R&D) growth is Bad.